Related Experiment Video

Updated: Apr 19, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Restoration of IRF1-dependent anticancer effects by MEK inhibition in human cancer cells

Nader AbuSara1, Seyd Razavi1, Leena Derwish1

  • 1Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.

Cancer Letters
|December 16, 2014
PubMed

Insights

Activated Ras/MEK signaling suppresses Interferon Regulatory Factor 1 (IRF1) in human cancers. IRF1 is crucial for Ras/MEK inhibition-induced apoptosis and antitumor gene expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Interferon regulatory factor (IRF1) is a key protein with antiviral, antitumor, and immune regulatory functions.
  • Activated Ras/MEK signaling has been shown to inhibit antiviral responses by downregulating IRF1.
  • This pathway also makes cancer cells more susceptible to oncolytic viruses.

Purpose of the Study:

  • To investigate if IRF1 downregulation is a mechanism driving oncogenesis in human cancer cells with activated Ras/MEK.
  • To understand the role of IRF1 in apoptosis and antitumor gene expression modulated by Ras/MEK inhibition.

Main Methods:

  • Treatment of human cancer cell lines with MEK inhibitors (e.g., U0126) and RNAi against extracellular signal-regulated kinases (ERKs).
  • Assessment of IRF1 expression levels following MEK inhibition.
  • Evaluation of antitumor gene expression (p27, PUMA) and apoptosis induction in IRF1 knockdown versus control cells.

Main Results:

  • MEK inhibition using U0126 increased IRF1 expression in 7 out of 11 tested cancer cell lines.
  • Similar IRF1 upregulation was observed with other MEK inhibitors and ERK RNAi.
  • Restoration of p27 and PUMA expression and apoptosis induction by MEK inhibition were significantly reduced in IRF1-deficient cells.

Conclusions:

  • Activated Ras/MEK signaling suppresses IRF1 expression in human cancer cells.
  • IRF1 plays a critical role in mediating apoptosis and regulating antitumor genes following Ras/MEK inhibition.
  • Targeting the Ras/MEK/IRF1 axis may offer therapeutic strategies for cancer treatment.
Keywords:
ApoptosisInterferon regulatory factor (IRF1)Ras/MEK

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

957
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K